利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.039 秒)

    Probes and primers for detection of bacterial pathogens and antibiotic resistance genes
    22.
    发明授权
    Probes and primers for detection of bacterial pathogens and antibiotic resistance genes 有权
    用于检测细菌病原体和抗生素抗性基因的探针和底物

    公开(公告)号：US07943346B2

    公开(公告)日：2011-05-17

    申请号：US11416499

    申请日：2006-05-01

    申请人： Michel G. Bergeron ,  Marc Ouellette ,  Paul H. Roy

    发明人： Michel G. Bergeron ,  Marc Ouellette ,  Paul H. Roy

    IPC分类号： C12P19/34 ,  C07H21/04

    CPC分类号： C07K14/315 ,  C07K14/195 ,  C07K14/21 ,  C07K14/212 ,  C07K14/245 ,  C07K14/26 ,  C07K14/285 ,  C07K14/31 ,  C07K14/3156 ,  C12Q1/689 ,  C12Q1/6895 ,  C12Q2600/16

    摘要： The present invention relates to methods for universal bacterial detection, for specific detection of the common bacterial pathogens, and for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The core of this invention consists primarily of the DNA sequences from all species-specific genomic DNA fragments selected by hybridization from genomic libraries or, alternatively, selected from data banks as well as any oligonucleotide sequences derived from these sequences which can be used as probes or amplification primers for PCR or any other nucleic acid amplification methods. This invention also includes DNA sequences from the selected clinically relevant antibiotic resistance genes. Diagnostic kits comprising such primers and probes are also provided.

    摘要翻译： 本发明涉及通用细菌检测方法，用于特异性检测常见细菌病原体，以及直接从临床标本或细菌菌落特异性检测常见且临床相关的细菌抗生素抗性基因。 本发明的核心主要由来自基因组文库杂交选择的所有物种特异性基因组DNA片段的DNA序列组成，或者选自数据库，以及衍生自可用作探针的这些序列的任何寡核苷酸序列， 用于PCR的扩增引物或任何其它核酸扩增方法。 本发明还包括来自所选择的临床相关抗生素抗性基因的DNA序列。 还提供了包括这种引物和探针的诊断试剂盒。

    SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES
    23.
    发明申请
    SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES 审中-公开

    公开(公告)号：US20090047671A1

    公开(公告)日：2009-02-19

    申请号：US11842092

    申请日：2007-08-20

    申请人： Michel G. Bergeron ,  Marc Quellette ,  Paul H. Roy

    发明人： Michel G. Bergeron ,  Marc Quellette ,  Paul H. Roy

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/689 ,  C07K14/195 ,  C07K14/21 ,  C07K14/212 ,  C07K14/245 ,  C07K14/26 ,  C07K14/285 ,  C07K14/31 ,  C07K14/315 ,  C07K14/3156 ,  C12N15/65 ,  C12Q2600/16

    摘要： The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The above bacterial species can account for as much as 80% of bacterial pathogens isolated in routine microbiology laboratories. The core of this invention consists primarily of the DNA sequences from all species-specific genomic DNA fragments selected by hybridization from genomic libraries or, alternatively, selected from data banks as well as any oligonucleotide sequences derived from these sequences which can be used as probes or amplification primers for PCR or any other nucleic acid amplification methods. This invention also includes DNA sequences from the selected clinically relevant antibiotic resistance genes. With these methods, bacteria can be detected (universal primers and/or probes) and identified (species-specific primers and/or probes) directly from the clinical specimens or from an isolated bacterial colony. Bacteria are further evaluated for their putative susceptibility to antibiotics by resistance gene detection (antibiotic resistance gene specific primers and/or probes). Diagnostic kits for the detection of the presence, for the bacterial identification of the above-mentioned bacterial species and for the detection of antibiotic resistance genes are also claimed. These kits for the rapid (one hour or less) and accurate diagnosis of bacterial infections and antibiotic resistance will gradually replace conventional methods currently used in clinical microbiology laboratories for routine diagnosis. They should provide tools to clinicians to help prescribe promptly optimal treatments when necessary. Consequently, these tests should contribute to saving human lives, rationalizing treatment, reducing the development of antibiotic resistance and avoid unnecessary hospitalizations.

    Methods and formulations for targeting infectious agents bearing host cell proteins
    27.
    发明授权
    Methods and formulations for targeting infectious agents bearing host cell proteins 有权
    用于靶向携带宿主细胞蛋白的传染原的方法和制剂

    公开(公告)号：US07357930B1

    公开(公告)日：2008-04-15

    申请号：US09980516

    申请日：2000-05-03

    申请人： Michel G. Bergeron ,  Andre Desormeaux ,  Michel J. Tremblay

    发明人： Michel G. Bergeron ,  Andre Desormeaux ,  Michel J. Tremblay

    IPC分类号： A61K9/127 ,  A61K39/00 ,  A61K31/7115 ,  A61K31/712

    CPC分类号： A61K9/1271 ,  A61K47/6913 ,  Y02A50/409 ,  Y10S514/934

    摘要： A formulation is disclosed for the treatment of diseases caused by an infectious agent which acquires host membranes protein during its life cycle. The formulation is a targeting pharmaceutical composition. It comprises a ligand capable of binding the host membrane proteins coupled to a lipid-comprising vesicle, which may comprise or not a drug effective in the treatment of the disease. Specific liposomes bearing anti-HLA-DR or anti-CD4 antibodies comprising or not antiviral drugs, namely anti-HIV drugs, are disclosed and claimed. A method of formulation as well as a method of using the formulation in the treatment of a disease are also disclosed.

    摘要翻译： 公开了用于治疗在其生命周期中获得宿主膜蛋白的感染因子引起的疾病的制剂。 制剂是靶向药物组合物。 其包含能够结合与包含脂质的囊泡结合的宿主膜蛋白的配体，其可以包含或不具有有效治疗疾病的药物。 公开并要求保护包含或不包含抗病毒药物，即抗HIV药物的抗HLA-DR或抗CD4抗体的特异性脂质体。 还公开了一种制剂的制备方法以及使用该制剂治疗疾病的方法。